PCSK9 inhibitors - mechanisms of action

Michael M Page, Gerald F Watts

    Research output: Contribution to journalArticle

    25 Citations (Scopus)

    Abstract

    PCSK9 is a proprotein convertase which is involved in the degradation of low-density lipoprotein (LDL) receptors in the liver. Mutations in the PCSK9 gene cause familial hypercholesterolaemia in a subset of patients by reducing the number of LDL receptors on the surface of hepatocytes. This decreases their ability to clear LDL cholesterol from plasma. Conversely, other PCSK9 mutations result in unusually low concentrations of plasma LDL cholesterol and a reduced risk of atherosclerotic disease. Blocking the activity of PCSK9 with monoclonal antibodies reduces the degradation of LDL receptors and increases the clearance of LDL cholesterol. An injection of PCSK9-specific antibody suppresses LDL-cholesterol concentrations for several weeks. © 2016, Australian Government Publishing Service. All Rights reserved.
    Original languageEnglish
    Pages (from-to)164-167
    Number of pages4
    JournalAustralian Prescriber
    Volume39
    Issue number5
    DOIs
    Publication statusPublished - Oct 2016

    Fingerprint Dive into the research topics of 'PCSK9 inhibitors - mechanisms of action'. Together they form a unique fingerprint.

    Cite this